drugset / Trial / NCT01335074
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Sorafenib is the standard therapy for advanced liver cancer but often shows dose-limiting toxicities with the need to reduce the applied dose of the compound. As this limits the overall response rate of the therapy, a combination with temsirolimus, an inhibitor of mTOR signaling, will be investigated regarding safety and tolerability in patients with advanced liver cancer under a reduced dose of sorafenib.
Timeline
- Start
- 2011-04
- Primary completion
- 2013-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 200 mg | — |
| Subject | Temsirolimus | Small molecule | 15 mg | — |
| Subject | Temsirolimus | Small molecule | 20 mg | — |
| Subject | Temsirolimus | Small molecule | 25 mg | — |